RT Journal Article
SR Electronic
T1 BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5445
OP 5452
DO 10.21873/anticanres.15356
VO 41
IS 11
A1 HIROFUMI SUZUMURA
A1 MASASHI TSURUTA
A1 KOJI OKABAYASHI
A1 KOHEI SHIGETA
A1 RYO SEISHIMA
A1 TAKASHI ISHIDA
A1 TAKEHIRO SHIMADA
A1 YUSUKE ASADA
A1 KAORU KOISHIKAWA
A1 SHINGO AKIMOTO
A1 OSAMU ITANO
A1 HIROTOSHI HASEGAWA
A1 YUKO KITAGAWA
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5445.abstract
AB Background/Aim: The role of brahma-related gene 1 (BRG1)-associated factor 57 (BAF57), a transcription factor, has been determined in prostate, breast, and ovarian cancer. However, the relationship between BAF57 and colorectal cancer (CRC) is obscure. Thus, we examined the functional correlation between BAF57 expression and oncological malignancy in CRC in vitro. Materials and Methods: BAF57 expression in WiDr and HT29 CRC cell lines and clinical specimens from CRC patients was analysed by western blotting and/or RT-PCR. BAF57 expression was down-regulated in WiDr cells through siRNA transfection. An invasion assay was also performed to assess malignancy. Results: BAF57 was expressed in both human CRC cell lines. Overall survival and recurrence-free survival rates were significantly reduced in high BAF57-expressing specimens. BAF57 expression was an independent predictive factor for long-term survival. Conclusion: BAF57 correlates with oncological malignancy and may be a novel therapeutic target in CRC.